Loading...
Employer Quick Look
Novartis is a world leader in the research and development of products to protect and improve health and well-being.
Novartis was created in 1996 from the merger of the Swiss companies, Ciba-Geigy and Sandoz.
Our core businesses are in pharmaceuticals, consumer health, generics, eye-care, and animal health. Our name, derived from the Latin novae artes, meaning "new skills," reflects our commitment to focus on research and development to bring innovative products to the communities we serve.
In 2004, the Group's businesses achieved sales of USD 28.2 billion and a net income of USD 5.8 billion. The Group invested approximately USD 4.3 billion in research and development (R&D). Headquartered in Basel, Switzerland, Novartis Group companies employ about 81 000 people and operate in over 140 countries around the world.
Novartis was created in 1996 from the merger of the Swiss companies, Ciba-Geigy and Sandoz.
Our core businesses are in pharmaceuticals, consumer health, generics, eye-care, and animal health. Our name, derived from the Latin novae artes, meaning "new skills," reflects our commitment to focus on research and development to bring innovative products to the communities we serve.
In 2004, the Group's businesses achieved sales of USD 28.2 billion and a net income of USD 5.8 billion. The Group invested approximately USD 4.3 billion in research and development (R&D). Headquartered in Basel, Switzerland, Novartis Group companies employ about 81 000 people and operate in over 140 countries around the world.
The Novartis benefits programs are an integral part of the total compensation policy and strategy and designed to meet the challenges of an evolving competition for talent on a global scale.
These programs are structured to support Novartis' overall business objectives and strategy. Benefits are aligned with local legislation and practices in each country and generally include pension plans, group life insurance, and medical plans. Some programs offer flexible mechanisms to tailor appropriate coverage for current and future needs and are established to provide a sound framework of security for our Novartis associates.
Novartis seeks EU approval for Exforge®, a powerful combination of two leading blood pressure medicines in a convenient once-daily tablet
Basel, March 3, 2006 - Novartis has submitted for European approval the new treatment Exforge® (amlodipine and valsartan) to help people with high blood pressure - the world's most common killer estimated to affect at least 25% of all adults1 - by combining two of the leading blood pressure-lowering medicines in one tablet.
Exforge, a combination of the calcium channel blocker amlodipine and the angiotensin receptor blocker valsartan, has been shown in clinical trials involving more than 5,000 patients to provide powerful blood pressure control with excellent safety and tolerability.2
Exforge is expected to help patients who struggle with the inconvenience of multiple medications while trying to reach their blood pressure goals. Significant reductions in both systolic and diastolic blood pressure were observed during the clinical trials, which also showed a lower incidence of peripheral edema (fluid retention) versus the use of amlodipine as a monotherapy2.
Novartis is seeking approval for Exforge for use in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy, and as replacement therapy for patients taking amlodipine and valsartan as a free combination - i.e. from separate tablets. A range of Exforge doses are planned to be made available following approval to help people with high blood pressure meet their treatment goals. In addition to the European Union, Exforge is on schedule to be submitted in 2006 for approval in the US as well as in other
- Exforge a combination of amlodipine and valsartan - two of the world's leading blood-pressure-lowering medicines
- Addresses significant unmet need for new combination therapies to help seven out of ten people who are not reaching their treatment goals
- Potential for best-in-class efficacy based on clinical data showing significant drop in systolic blood pressure
Basel, March 3, 2006 - Novartis has submitted for European approval the new treatment Exforge® (amlodipine and valsartan) to help people with high blood pressure - the world's most common killer estimated to affect at least 25% of all adults1 - by combining two of the leading blood pressure-lowering medicines in one tablet.
Exforge, a combination of the calcium channel blocker amlodipine and the angiotensin receptor blocker valsartan, has been shown in clinical trials involving more than 5,000 patients to provide powerful blood pressure control with excellent safety and tolerability.2
Exforge is expected to help patients who struggle with the inconvenience of multiple medications while trying to reach their blood pressure goals. Significant reductions in both systolic and diastolic blood pressure were observed during the clinical trials, which also showed a lower incidence of peripheral edema (fluid retention) versus the use of amlodipine as a monotherapy2.
Novartis is seeking approval for Exforge for use in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy, and as replacement therapy for patients taking amlodipine and valsartan as a free combination - i.e. from separate tablets. A range of Exforge doses are planned to be made available following approval to help people with high blood pressure meet their treatment goals. In addition to the European Union, Exforge is on schedule to be submitted in 2006 for approval in the US as well as in other
We want to discover, develop and successfully market innovative products to cure diseases, to ease suffering, and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.
Calcium Sandoz®
Mineral supplement
Denavir®/Vectavir®
Cold sore treatment
Ex-Lax®
Overnight laxative
Fenistil®
Skin irritation treatment
Gas X®
Adult gas relief
Lamisil®AT
Topical Antifungal agent
Maalox®
Antacid
Nicotinell®
Smoking cessation
Otrivin®
Nasal decongestant
Theraflu/Neocitran®
Treats adult cold and flu
Triaminic®
Treats pediatric cough and cold
Voltaren® Emulgel
Anti inflammatory pain relief gel
Also available in the US:
4-Way®
Nasal decongestant
Bufferin®
Systemic analgesic
Comtrex®
Cold and flu
Excedrin®
Systemic analgesic
Keri®
Skin care
Mineral Ice®
Topical analgesic
No-Doz®
Sleep
Vagistat®
Antifungal
Diovan® / Co-Diovan®
(valsartan)
Used in the treatment of hypertension
GleevecTM/Glivec®
(imatinib mesylate)
Used in the treatment of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST)
Lamisil® (group)
(terbinafine HCI)
Antifungal agent
Zometa®
(zoledronic acid)
Used in the treatment of bone metastasis in a variety of tumor types
Neoral / Sandimmun®
(ciclosporin)
Immunosuppressive agent for transplantations
More information (US residents only)
Lotrel®
(amlodipine and benazepril hydrochloride)
Used in the treatment of hypertension
Sandostatin® / LAR®
(octreotide acetate)
Used to reduce blood levels of growth hormone and IGF-I in acromegaly patients
Lescol®
(fluvastatin sodium)
Used in the treatment of atherosclerosis vascular disease
Voltaren® (group)
(diclofenac sodium)
Nonsteroidalanti-inflammatory, antirheumatic agent
Trileptal®
(oxcarbazepine)
Used in the treatment of epilepsy
Mineral supplement
Denavir®/Vectavir®
Cold sore treatment
Ex-Lax®
Overnight laxative
Fenistil®
Skin irritation treatment
Gas X®
Adult gas relief
Lamisil®AT
Topical Antifungal agent
Maalox®
Antacid
Nicotinell®
Smoking cessation
Otrivin®
Nasal decongestant
Theraflu/Neocitran®
Treats adult cold and flu
Triaminic®
Treats pediatric cough and cold
Voltaren® Emulgel
Anti inflammatory pain relief gel
Also available in the US:
4-Way®
Nasal decongestant
Bufferin®
Systemic analgesic
Comtrex®
Cold and flu
Excedrin®
Systemic analgesic
Keri®
Skin care
Mineral Ice®
Topical analgesic
No-Doz®
Sleep
Vagistat®
Antifungal
Diovan® / Co-Diovan®
(valsartan)
Used in the treatment of hypertension
GleevecTM/Glivec®
(imatinib mesylate)
Used in the treatment of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST)
Lamisil® (group)
(terbinafine HCI)
Antifungal agent
Zometa®
(zoledronic acid)
Used in the treatment of bone metastasis in a variety of tumor types
Neoral / Sandimmun®
(ciclosporin)
Immunosuppressive agent for transplantations
More information (US residents only)
Lotrel®
(amlodipine and benazepril hydrochloride)
Used in the treatment of hypertension
Sandostatin® / LAR®
(octreotide acetate)
Used to reduce blood levels of growth hormone and IGF-I in acromegaly patients
Lescol®
(fluvastatin sodium)
Used in the treatment of atherosclerosis vascular disease
Voltaren® (group)
(diclofenac sodium)
Nonsteroidalanti-inflammatory, antirheumatic agent
Trileptal®
(oxcarbazepine)
Used in the treatment of epilepsy
Novartis International AG
CH-4002 Basel
Switzerland
Novartis International AG
Tel: +41 61 324 11 11
Fax: +41 61 324 80 01
CH-4002 Basel
Switzerland
Novartis International AG
Tel: +41 61 324 11 11
Fax: +41 61 324 80 01
As a global company, Novartis reflects by definition a great diversity of cultural backgrounds. But our scope with diversity goes beyond culture, and incorporates many visible and invisible differences, including among others, leadership and thinking styles, gender, ethnicity, religion, sexual orientation, age and experience.
Our Diversity & Inclusion strategies are conscious efforts to fully derive and leverage the value available from diversity, with the performance interests of the business at heart.
If we cast the net widely and proactively across all segments of the talent market, then we will be successful in attracting our share of the best available talent. If we integrate multiple perspectives into our idea generation and decision making processes, then we heighten the probability of greater creativity and innovation in our outcomes. And if we reflect the diversified marketplace in our internal demographic, then we will be better positioned to understand our customers, to incorporate their insights into our products, and to serve them with excellence. In short we will consolidate competitive advantage.
Ensuring diversity of representations and complementarities across our internal teams and communities is the starting point. It takes inclusive leadership, in spirit and in practice, to secure the strategy’s success. Only by motivating positive team dynamics and productivity, leveraging the differences, and bringing about the best possible contribution from each individual, can we deliver on the promise of diversity.
Our Diversity & Inclusion strategies are conscious efforts to fully derive and leverage the value available from diversity, with the performance interests of the business at heart.
If we cast the net widely and proactively across all segments of the talent market, then we will be successful in attracting our share of the best available talent. If we integrate multiple perspectives into our idea generation and decision making processes, then we heighten the probability of greater creativity and innovation in our outcomes. And if we reflect the diversified marketplace in our internal demographic, then we will be better positioned to understand our customers, to incorporate their insights into our products, and to serve them with excellence. In short we will consolidate competitive advantage.
Ensuring diversity of representations and complementarities across our internal teams and communities is the starting point. It takes inclusive leadership, in spirit and in practice, to secure the strategy’s success. Only by motivating positive team dynamics and productivity, leveraging the differences, and bringing about the best possible contribution from each individual, can we deliver on the promise of diversity.